Abeona Therapeutics (ABEO) Total Current Liabilities (2010 - 2026)

Abeona Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $31.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 72.64% year-over-year to $31.0 million in Q1 2026; TTM through Mar 2026 was $31.0 million, a 72.64% increase from a year earlier, with the FY2025 full-year figure at $29.6 million, up 78.27% from the prior year.
• Total Current Liabilities grew to $31.0 million in Q1 2026 per ABEO's latest filing, from $29.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $34.5 million in Q2 2025 and bottomed at $7.4 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $13.7 million (2022), against an average of $16.7 million.
• Across the five-year window, Total Current Liabilities slumped 69.79% in 2022 and soared 119.0% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $7.8 million in 2022, then jumped by 72.54% to $13.4 million in 2023, then increased by 23.58% to $16.6 million in 2024, then surged by 78.27% to $29.6 million in 2025, then grew by 4.99% to $31.0 million in 2026.
• Per Business Quant, the three latest ABEO Total Current Liabilities figures stand at $31.0 million (Q1 2026), $29.6 million (Q4 2025), and $22.2 million (Q3 2025).